Liver, lung and malignant disease in heterozygous (Pi MZ) alpha1-antitrypsin deficiency

Acta Med Scand. 1975 Oct;198(4):243-7. doi: 10.1111/j.0954-6820.1975.tb19535.x.

Abstract

Theoccurrence of PAS-positive, diastase-resistant, inclusion bodies in hepatocytes has been used as a marker of heterozygous (Pi MZ) alpha1-antitrypsin deficiency in order to study the frequency of lung, liver and malignant disease in a consecutive autopsy material from a well defined population. Typical PAS-positive inclusion bodies were found in the liver in 26 (3.7%) of the 700 cases studied. In these 26 subjects both liver (cirrhosis or fibrosis) and lung disease (emphysema) were significantly more prevalent (p less than 0.001) than among PAS-negative controls. The prevalence of malignant disease did not differ between the groups. The results are consistent with the concept that heterozygous (Pi MZ) alpha1-antitrypsin deficiency predisposes to both liver and lung disease but does not influence the survival rate.

MeSH terms

  • Aged
  • Aminosalicylic Acids
  • Autopsy
  • Blood Protein Disorders / complications
  • Heterozygote
  • Histocytochemistry
  • Humans
  • Inclusion Bodies / analysis
  • Liver / pathology
  • Liver Diseases / enzymology*
  • Liver Diseases / genetics
  • Lung Diseases / enzymology*
  • Lung Diseases / genetics
  • Mass Screening
  • Middle Aged
  • alpha 1-Antitrypsin Deficiency*

Substances

  • Aminosalicylic Acids